EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Antimicrobial-resistant Pseudomonas aeruginosa in the USA: implications of a national surveillance gap

Richard R Watkins, Tracy L Lemonovich, Robert A Bonomo

Journal of Antimicrobial Chemotherapy · 2026-11-03 · 81 (12)

DOI: 10.1093/jac/dkag382 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Surveillance data for Pseudomonas aeruginosa in the USA are distributed across systems designed for different purposes, potentially limiting standardized national surveillance of high-priority resistant phenotypes. We evaluated whether the Centers for Disease Control and Prevention (CDC) National Notifiable Diseases Surveillance System (NNDSS) can support surveillance of multidrug-resistant (MDR) P. aeruginosa and synthesized available CDC surveillance data to characterize the residual surveillance gap. Methods We reviewed the 2026 NNDSS list of nationally notifiable conditions for P. aeruginosa. Because neither P. aeruginosa infection nor a resistant phenotype was present, NNDSS case counts were unable to be analysed. We therefore conducted a descriptive secondary analysis of CDC National Healthcare Safety Network (NHSN) reports for 2018–21 and the 2022 NHSN Antimicrobial Resistance (AR) Option report. Results In 2018–21 adult NHSN data, 11.9% of tested P. aeruginosa isolates from device-associated infections were MDR, compared with 3.9% from surgical-site infections. Among central-line-associated bloodstream infection isolates, MDR proportions were highest in long-term acute-care hospitals (LTACHs, 25.3%), followed by hospital intensive-care units (14.2%), hospital wards (11.9%) and oncology units (8.5%). Among catheter-associated urinary tract infection isolates, MDR phenotype was observed in 20.8% of LTACH isolates. In the 2022 AR Option report, carbapenem non-susceptibility exceeded 10% among community-onset isolates and approached 20% among hospital-onset isolates. Conclusions NNDSS cannot currently quantify the burden of MDR P. aeruginosa, but substantial resistance surveillance is available through NHSN and the CDC AR Laboratory Network. The principal gap is not an absence of surveillance data but fragmentation across systems with different populations, denominators, objectives and reporting mechanisms.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →